Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1991 Dec;59(12):4349–4356. doi: 10.1128/iai.59.12.4349-4356.1991

Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers.

G Arakere 1, C E Frasch 1
PMCID: PMC259048  PMID: 1937795

Abstract

Most group C Neisseria meningitidis strains produce an O-acetyl-positive polysaccharide, a homopolymer of alpha-2----9-linked N-acetylneuraminic acid with O-acetyl groups at the C-7 and C-8 of its sialic acid residues. The majority of disease isolates have been reported to contain this polysaccharide. Some strains produce group C polysaccharide lacking O-acetyl groups. The licensed vaccine contains the O-acetyl-positive polysaccharide. We have measured the antibody specificities to the two polysaccharides in sera from asymptomatic group C meningococcal carriers and vaccinated adults by a new enzyme-linked immunosorbent assay (ELISA) procedure using methylated human serum albumin for coating the group C polysaccharide onto microtiter plates. Inhibition of binding of serum antibodies to polysaccharide-coated plates was measured by ELISA after incubation with O-acetyl-positive and O-acetyl-negative group C polysaccharides. Greater inhibition of binding of carrier sera was observed with the homologous polysaccharide. There was substantial inhibition of binding of vaccinee sera to the O-acetyl-positive polysaccharide-coated plate following preincubation with O-acetyl-positive polysaccharide, but homologous inhibition on plates coated with the O-acetyl-negative polysaccharide required much higher concentrations of polysaccharide. Carrier sera may have a higher proportion of antibodies with greater specificity for the O-acetyl-negative polysaccharide, while vaccinee sera contain antibodies with greater affinity for the O-acetyl-positive polysaccharide. Studies with monoclonal antibodies specific for O-acetyl-positive and O-acetyl-negative polysaccharides reveal that the percentage of group C meningococcal disease caused by O-acetyl-negative strains remains about 15%, as found over 15 years ago.

Full text

PDF
4349

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apicella M. A., Feldman H. A. Meningococcal group C subgroup determinant detected by immunofluorescence. Proc Soc Exp Biol Med. 1976 Jul;152(3):289–291. doi: 10.3181/00379727-152-39381. [DOI] [PubMed] [Google Scholar]
  2. Apicella M. A. Identification of a subgroup antigen on the Neisseria meningitidis group C capsular polysaccharide. J Infect Dis. 1974 Feb;129(2):147–153. doi: 10.1093/infdis/129.2.147. [DOI] [PubMed] [Google Scholar]
  3. Artenstein M. S., Gold R., Zimmerly J. G., Wyle F. A., Schneider H., Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970 Feb 19;282(8):417–420. doi: 10.1056/NEJM197002192820803. [DOI] [PubMed] [Google Scholar]
  4. Barra A., Schulz D., Aucouturier P., Preud'homme J. L. Measurement of anti-Haemophilus influenzae type b capsular polysaccharide antibodies by ELISA. J Immunol Methods. 1988 Nov 25;115(1):111–117. doi: 10.1016/0022-1759(88)90317-1. [DOI] [PubMed] [Google Scholar]
  5. Beuvery E. C., Kayhty M. H., Leussink A. B., Kanhai V. Comparison of radioimmunoassay and enzyme-linked immunosorbent assay in measurement of antibodies to Neisseria meningitidis group A capsular polysaccharide. J Clin Microbiol. 1984 Oct;20(4):672–676. doi: 10.1128/jcm.20.4.672-676.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Broome C. V. The carrier state: Neisseria meningitidis. J Antimicrob Chemother. 1986 Jul;18 (Suppl A):25–34. doi: 10.1093/jac/18.supplement_a.25. [DOI] [PubMed] [Google Scholar]
  7. Corneo G., Zardi L., Polli E. Elution of human satellite DNAs on a methylated albumin kieselguhr chromatographic column: isolation of satellite DNA. IV. Biochim Biophys Acta. 1972 May 10;269(2):201–204. doi: 10.1016/0005-2787(72)90427-3. [DOI] [PubMed] [Google Scholar]
  8. Frasch C. E., Peppler M. S. Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens. Infect Immun. 1982 Jul;37(1):271–280. doi: 10.1128/iai.37.1.271-280.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Frasch C. E., Robbins J. D. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J Exp Med. 1978 Mar 1;147(3):629–644. doi: 10.1084/jem.147.3.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Frasch C. E. Role of protein serotype antigens in protection against disease due to Neisseria meningitidis. J Infect Dis. 1977 Aug;136 (Suppl):S84–S90. doi: 10.1093/infdis/136.supplement.s84. [DOI] [PubMed] [Google Scholar]
  11. Glode M. P., Lewin E. B., Sutton A., Le C. T., Gotschlich E. C., Robbins J. B. Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers. J Infect Dis. 1979 Jan;139(1):52–59. doi: 10.1093/infdis/139.1.52. [DOI] [PubMed] [Google Scholar]
  12. Goldschneider I., Gotschlich E. C., Artenstein M. S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969 Jun 1;129(6):1307–1326. doi: 10.1084/jem.129.6.1307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gotschlich E. C. Development of polysaccharide vaccines for the prevention of meningococcal diseases. Monogr Allergy. 1975;9:245–258. [PubMed] [Google Scholar]
  14. Jones D. M., Eldridge J. Development of antibodies to meningococcal protein and lipopolysaccharide serotype antigens in healthy-carriers. J Med Microbiol. 1979 Feb;12(1):107–111. doi: 10.1099/00222615-12-1-107. [DOI] [PubMed] [Google Scholar]
  15. Kothari R. M., Shankar V., Taylor M. W. RNA fractionation on Kieselguhr columns. J Chromatogr. 1972 Aug 23;70(2):341–363. doi: 10.1016/s0021-9673(00)92701-8. [DOI] [PubMed] [Google Scholar]
  16. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  17. Leinonen M., Frasch C. E. Class-specific antibody response to group B Neisseria meningitidis capsular polysaccharide: use of polylysine precoating in an enzyme-linked immunosorbent assay. Infect Immun. 1982 Dec;38(3):1203–1207. doi: 10.1128/iai.38.3.1203-1207.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. MANDELL J. D., HERSHEY A. D. A fractionating column for analysis of nucleic acids. Anal Biochem. 1960 Jun;1:66–77. doi: 10.1016/0003-2697(60)90020-8. [DOI] [PubMed] [Google Scholar]
  19. Reller L. B., MacGregor R. R., Beaty H. N. Bactericidal antibody after colonization with Neisseria meningitidis. J Infect Dis. 1973 Jan;127(1):56–62. doi: 10.1093/infdis/127.1.56. [DOI] [PubMed] [Google Scholar]
  20. Rubinstein L. J., Stein K. E. Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. I. Ontogeny. J Immunol. 1988 Dec 15;141(12):4352–4356. [PubMed] [Google Scholar]
  21. Rubinstein L. J., Stein K. E. Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. II. Specificity. J Immunol. 1988 Dec 15;141(12):4357–4362. [PubMed] [Google Scholar]
  22. SVENNERHOLM L. Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta. 1957 Jun;24(3):604–611. doi: 10.1016/0006-3002(57)90254-8. [DOI] [PubMed] [Google Scholar]
  23. Steinhoff M. C., Lewin E. B., Gotschlich E. C., Robbins J. B. Group C Neisseria meningitidis variant polysaccharide vaccines in children. Infect Immun. 1981 Oct;34(1):144–146. doi: 10.1128/iai.34.1.144-146.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Thomas J. C., Bendana N. S., Waterman S. H., Rathbun M., Arakere G., Frasch C. E., Wenger J. D., Magsombol V., Clark J. H. Risk factors for carriage of meningococcus in the Los Angeles County men's jail system. Am J Epidemiol. 1991 Feb 1;133(3):286–295. doi: 10.1093/oxfordjournals.aje.a115873. [DOI] [PubMed] [Google Scholar]
  25. Zollinger W. D., Boslego J., Frøholm L. O., Ray J. S., Moran E. E., Brandt B. L. Human bactericidal antibody response to meningococcal outer membrane protein vaccines. Antonie Van Leeuwenhoek. 1987;53(6):403–411. doi: 10.1007/BF00415494. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES